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Summary
Background Microbiological characterisation of co-infections and secondary infections in patients with COVID-19 is 
lacking, and antimicrobial use is high. We aimed to describe microbiologically confirmed co-infections and secondary 
infections, and antimicrobial use, in patients admitted to hospital with COVID-19.
Methods The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) WHO Clinical 
Characterisation Protocol UK (CCP-UK) study is an ongoing, prospective cohort study recruiting inpatients from 
260 hospitals in England, Scotland, and Wales, conducted by the ISARIC Coronavirus Clinical Characterisation 
Consortium. Patients with a confirmed or clinician-defined high likelihood of SARS-CoV-2 infection were eligible for 
inclusion in the ISARIC WHO CCP-UK study. For this specific study, we excluded patients with a recorded negative 
SARS-CoV-2 test result and those without a recorded outcome at 28 days after admission. Demographic, clinical, 
laboratory, therapeutic, and outcome data were collected using a prespecified case report form. Organisms considered 
clinically insignificant were excluded.
Findings We analysed data from 48 902 patients admitted to hospital between Feb 6 and June 8, 2020. The median 
patient age was 74 years (IQR 59–84) and 20 786 (42·6%) of 48 765 patients were female. Microbiological investigations 
were recorded for 8649 (17·7%) of 48 902 patients, with clinically significant COVID-19-related respiratory or 
bloodstream culture results recorded for 1107 patients. 762 (70·6%) of 1080 infections were secondary, occurring 
more than 2 days after hospital admission. Staphylococcus aureus and Haemophilus influenzae were the most common 
pathogens causing respiratory co-infections (diagnosed ≤2 days after admission), with Enterobacteriaceae and 
S aureus most common in secondary respiratory infections. Bloodstream infections were most frequently caused by 
Escherichia coli and S aureus. Among patients with available data, 13 390 (37·0%) of 36 145 had received antimicrobials 
in the community for this illness episode before hospital admission and 39 258 (85·2%) of 46 061 patients with 
inpatient antimicrobial data received one or more antimicrobials at some point during their admission (highest for 
patients in critical care). We identified frequent use of broad-spectrum agents and use of carbapenems rather than 
carbapenem-sparing alternatives.
Interpretation In patients admitted to hospital with COVID-19, microbiologically confirmed bacterial infections are 
rare, and more likely to be secondary infections. Gram-negative organisms and S aureus are the predominant 
pathogens. The frequency and nature of antimicrobial use are concerning, but tractable targets for stewardship 
interventions exist.
Funding National Institute for Health Research (NIHR), UK Medical Research Council, Wellcome Trust, UK 
Department for International Development, Bill & Melinda Gates Foundation, EU Platform for European Preparedness 
Against (Re-)emerging Epidemics, NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic 
Infections at University of Liverpool, and NIHR HPRU in Respiratory Infections at Imperial College London.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Bacterial co-infections and secondary infections are 
commonly identified in severe influenza (23% in a 
meta-analysis)1 and other severe respiratory viral 
infections, in which they are associated with increased 
morbidity and mortality.2 National and international 
COVID-19 guidelines vary in their recommendations on 
empirical antimicrobial therapy—some recommend 
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empirical antimicrobial therapy in severe disease,3,4 
whereas others do not.5 UK guidelines advise against 
empirical therapy when lower respiratory tract infection 
is thought to be due to COVID-19, without specific 
evidence of bacterial infection.6,7 Living systematic 
reviews and meta-analyses have reported a low prevalence 
of confirmed bacterial co-infection (8%), but a high 
proportion of patients with COVID-19 received 
antimicrobials (pooled prevalence 75%).8,9 The collective 
implication of these studies is a widespread failure of 
antimicrobial stewardship with the potential to worsen 
the global antimicrobial resistance crisis.10
Most studies to date have been retrospective with 
small sample sizes, and few have systematically reported 
the spectrum of bacteria, timing of infection onset, or 
described the frequency and nature of antimicrobials 
used to treat them. There is an urgent need to 
characterise the causes of bacterial infections in patients 
admitted to hospital with COVID-19 to determine 
optimal empirical antimicrobial management strategies 
and identify targets for antimicrobial stewardship 
interventions.
In this prospective, multicentre, cohort study of patients 
admitted to hospital with COVID-19, we aimed to report 
the microbiological details of laboratory-confirmed co-
infections and secondary infections identified by culture-
based diagnostics, assess the effect of COVID-19-related 
co-infection on in-hospital mortality among patients 
admitted to critical care, and evaluate the nature of 
antimicrobial usage.
Methods
Study design and setting
The International Severe Acute Respiratory and Emerging 
Infections Consortium (ISARIC) WHO Clinical Characte-
risation Protocol UK (CCP-UK) study is an ongoing, 
prospective cohort study recruiting inpatients from 
260 hospitals in England, Scotland, and Wales (National 
Institute for Health Research [NIHR] Clinical Research 
Network Central Portfolio Management System ID 14152) 
and conducted by the ISARIC Coronavirus Clinical 
Characterisation Consortium (ISARIC4C). Ethics approval 
was given by the South Central—Oxford C Research 
Ethics Committee in England (13/SC/0149), the Scotland 
A Research Ethics Committee (20/SS/0028), and the 
WHO Ethics Review Committee (RPC571 and RPC572; 
April, 2013). The study protocol and further details are 
available online.11 This report of microbiological findings 
Research in context
Evidence before this study
An understanding of co-infections, secondary infections, and 
patterns of antimicrobial use in patients with COVID-19 is 
required to inform optimal empirical antimicrobial 
management strategies. We searched PubMed on Dec 29, 2020, 
for studies published in English, using the keywords 
“COVID-19”, “SARS-CoV-2”, “bacterial infection”, “bacterial 
pneumonia”, “superinfection”, “co-infection”, “secondary 
infection”, and “nosocomial infection”. Systematic reviews were 
included in the search. A low incidence of bacterial respiratory 
and bloodstream infections has been consistently reported in 
patients admitted to hospital with COVID-19. This finding is 
supported by a systematic review and meta-analysis, but 
individual studies lack granularity in microbiological and clinical 
details, are retrospective, and report on small cohorts. 
The timing of infection (co-infection or secondary infection) 
is often unknown. Reporting of positive results has lacked 
species-level detail on cultured organisms and exclusion of 
clinically irrelevant pathogens. PCR-based bacterial diagnosis is 
associated with higher pathogen detection than culture-based 
methods. Antimicrobial use in inpatients appears to be high, 
but studies infrequently report the drug classes used.
Added value of this study
This is a large, multicentre, prospective cohort study reporting 
microbiological findings and antimicrobial use in patients 
admitted to hospital with COVID-19 undergoing standardised 
microbiological investigation of samples submitted by clinical 
teams (UK Standards for Microbiology Investigations). 
Microbiologically confirmed bacterial co-infection (≤2 days after 
admission) and secondary infections (>2 days after admission) 
were uncommon in patients admitted to hospital with COVID-19, 
supporting the findings of a meta-analysis of smaller studies. 
When they did occur, bloodstream and respiratory infections were 
more likely to be secondary infections and Gram-negative 
organisms and Staphylococcus aureus were key aetiological agents, 
adding granularity in microbiological detail. Aetiology was 
affected by the timing of infection onset (co-infection or 
secondary infection), critical care admission, and chronic 
pulmonary disease. We confirmed high inpatient antimicrobial 
usage, additionally finding evidence of regional variation, 
frequent use of broad-spectrum empirical therapy for lower 
respiratory tract infections (β-lactam–β-lactamase inhibitor 
combinations), and use of carbapenems rather than 
carbapenem-sparing alternatives.
Implications of all the available evidence
Bacterial co-infections and secondary infections are rare in 
patients admitted to hospital with COVID-19. Most infections 
are secondary. Gram-negative organisms and S aureus are 
important pathogens and should be considered when 
designing empirical antimicrobial guidelines, but emphasis 
should be placed on restricting empirical prescribing, 
especially at hospital admission. The high frequency and 
nature of inpatient antimicrobial use might have long-term 
negative consequences for antimicrobial resistance. 
Specific targets exist for antimicrobial stewardship and 
should be integrated into COVID-19 patient care pathways.
For the study protocol see 
www.isaric4c.net/protocols
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See Online for appendix
and antimicrobial use from the study has been prepared in 
accordance with the STROBE statement.
Study participants and data collection
Patients with a confirmed or clinician-defined high 
likelihood of SARS-CoV-2 infection were eligible for 
inclusion in the ISARIC WHO CCP-UK study. For this 
specific study, we excluded patients with a recorded 
negative SARS-CoV-2 test result and those without a 
recorded outcome at 28 days after admission (discharged 
alive and expected to survive, palliative discharge 
[not expected to survive], ongoing hospitalisation, transfer 
to another facility [eg, for rehabilitation], or death). 
Demographic, clinical, laboratory, therapeutic, and 
outcome data were collected using a prespecified case 
report form. Comorbidities were defined by a modified 
Charlson comorbidity index and obesity was clinician 
defined. Data were uploaded to a Research Electronic 
Data Capture Database (REDCap; Vanderbilt University, 
Nashville, TN USA; hosted by University of Oxford, 
Oxford, UK).12 The requirement for consent for data 
collection was waived in view of the public health 
emergency.
Infection data processing
Microbiological data comprising organism name(s), 
specimen type, result status, and date of sample were 
recorded as a combination of dropdown fields and free 
text in REDCap. Results of superficial microbiology, 
screening swabs, and serology were excluded because of 
insufficient clinical information to allow interpretation. 
Additionally, respiratory viruses other than SARS-CoV-2 
were excluded since most laboratories prioritised 
SARS-CoV-2 over multiplex PCR testing during the 
first wave of the pandemic. Except for urine samples, 
staphylococci, other than Staphylococcus aureus and 
Staphylococcus lugdunensis, were considered clinically 
insignificant and excluded. Unspecified organisms 
(including positive microscopy findings with no culture 
result recorded) and results recorded as mixed growth or 
contaminant were excluded from all sample types. 
Corynebacterium sp and Cutibacterium sp were excluded 
from blood cultures. Candida sp were excluded from 
respiratory samples.
Positive cultures from blood, sputum, or deep 
respiratory tract (endotracheal aspirate, bronchoalveolar 
lavage, and pleural fluid) samples were considered 
possible COVID-19-related infections, while growth 
from other sample types was considered unrelated. 
Clinically significant positive results from samples 
collected within 2 days of admission were categorised as 
co-infections, and those collected more than 2 days after 
admission as secondary infections, synonymous with 
hospital onset or hospital-acquired infection.13 A patient 
could be recorded as having multiple infections, based 
on different sample types and different timepoints, 
during their admission.
Antimicrobials prescribed over the course of admission 
were entered as free text and mapped to drug names 
found in the UK National Health Service Technology 
Reference Data Update Distribution system.
Statistical analysis
Categorical variables are summarised as frequencies 
and percentages. Continuous variables are presented as 
means and SDs or medians and IQRs, depending on 
data distribution. Analysis of antimicrobial co-occurrence 
was done using the Jaccard similarity index and 
represented visually as heatmaps. p≤0·05 was considered 
to indicate a statistically significant difference. All 
statistical analyses were done using R version 3.6.3 using 
the Tidyverse, finalfit, stringdist, and fuzzyjoin packages.
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
We analysed data from 48 902 patients admitted to hospital 
between Feb 6 and June 8, 2020 (figure 1). The median 
patient age was 74 years (IQR 59–84) and 20 786 (42·6%) of 
48 765 patients were female (table). The most common 
comorbidities were chronic cardiac disease and chronic 
pulmonary disease excluding asthma (table). 13 390 (37·0%) 
of 36 145 patients had received antimicrobials in the 
community for this illness episode before hospital 
admission. Vital signs and laboratory results on admission 
are shown in the appendix (p 1). 31 422 (69·2%) of 
45 420 patients received supplemental oxygen during 
their hospital stay, 6755 (14·9%) of 45 420 patients 
received non-invasive ventilation, and 4241 (9·3%) of 
45 607 patients received invasive mechanical ventilation 
(table). 7090 (14·5%) of 48 902 patients required admission 
to critical care (high dependency or intensive care unit). 
15 392 (31·5%) of 48 902 inpatients died in hospital.
Microbiological investigations were recorded for 
8649 (17·7%) of 48 902 patients (figure 1; appendix p 1). 
Characteristics of this subgroup of patients are presented 
in the appendix (p 2). After exclusion of negative 
and non-significant results, we observed 2109 clinically 
significant results for 1942 patients. Patients admitted 
to critical care were more likely to have a documented 
blood or respiratory culture than ward-level patients 
(2163 [30·5%] of 7090 patients vs 5430 [13·0%] of 
41 812 patients; p<0·0001). Positivity rates of recorded 
cultures were high—602 (42·1%) of 1429 cultures for 
sputum, 207 (51·5%) of 402 cultures for deep respiratory 
samples, and 500 (8·1%) of 6157 cultures for blood. We 
concluded that there was a bias towards recording 
positive results; therefore, we elected not to estimate the 
incidence of any infection within the cohort, restricting 
the reporting of proportions to identified organisms 
within positive samples.
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We identified 1107 patients with COVID-19-related 
infections (positive blood, sputum, or deep respiratory 
cultures) and 1002 patients with unrelated infections 
(urine, abdominopelvic, or pus or abscess cultures). 
For microbiologically confirmed COVID-19-related 
infections where sample timing was known, 762 (70·6%) 
of 1080 infections were secondary, occurring more than 
2 days after hospital admission. Among patients 
admitted to critical care, we found no association 
between patients identified to have a respiratory or 
bloodstream infection and inpatient mortality on 
univariable analysis (unadjusted odds ratio 1·02, 95% CI 
0·86–1·22; p=0·81).
607 respiratory infections were recorded. Most culture-
positive respiratory samples represented secondary 
infections (919 [84·9%] of 1082 sputum and deep 
respiratory cultures; figure 2A). In lower respiratory tract 
co-infections (within 2 days of admission), S aureus 
(21 [17·8%] of 118 organisms), Haemophilus influenzae 
(15 [12·7%] organisms), and Pseudomonas aeruginosa 
(11 [9·3%] organisms) were most frequently identified 
in sputum (figure 2). Streptococcus pneumoniae was 
n Patients with COVID-19
Demographics
Sex 48 765 ··
Male ·· 27 979 (57·4%)
Female ·· 20 786 (42·6%)
Age, years 48 902 74·0 (59·0–84·0)
Comorbidities
Chronic cardiac disease 45 781 14 775 (32·3%)
Hypertension 22 006 10 645 (48·4%)
Chronic pulmonary disease 45 909 13 169 (28·7%)
Immunocompromise 25 742 7548 (29·3%)
Asthma 45 470 6309 (13·9%)
Chronic kidney disease 45 451 8092 (17·8%)
Chronic liver disease (moderate or severe) 45 001 867 (1·9%)
Chronic liver disease (mild) 44 880 683 (1·5%)
Chronic neurological disease 45 187 5747 (12·7%)
Current malignancy 45 067 4730 (10·5%)
Chronic haematological disease 45 019 1984 (4·4%)
HIV/AIDS 44 510 184 (0·4%)
Obesity* 41 058 4877 (11·9%)
Diabetes 46 180 13 581 (29·4%)
Rheumatological disease 44 946 5065 (11·3%)
Dementia 45 310 7534 (16·6%)
Smoking 31 125 ··
Never ·· 17 953 (57·7%)
Former ·· 10 825 (34·8%)
Current ·· 2347 (7·5%)
Pre-admission
Symptom duration before admission, days ·· 4·0 (1·0–8·0)
Receipt of antimicrobials before admission 36 145 13 390 (37·0%)
Maximum level of respiratory support
Non-invasive ventilation 45 420 6755 (14·9%)
Invasive mechanical ventilation 45 607 4241 (9·3%)
Other organ support
Renal replacement therapy 44 803 1508 (3·4%)
Vasopressors 44 672 2987 (6·7%)
Medical management
Antibacterial 46 061 39 258 (85·2%)
Antifungal 48 902 309 (0·6%)
Corticosteroids 48 902 4850 (9·9%)
Outcomes
Outcome at ≥28 days 48 902 ··
Discharged alive and expected to survive ·· 28 819 (58·9%)
Ongoing hospitalisation ·· 1186 (2·4%)
Transfer to other facility ·· 2623 (5·4%)
Inpatient death ·· 15 392 (31·5%)
Palliative discharge ·· 869 (1·8)
Unknown or awaited ·· 13 (<0·1%)
Length of stay, days† ·· 9·0 (4·0–17·0)
Data are n (%) or median (IQR). *Clinician defined. †Excludes patients remaining in hospital after 28 days.
Table: Baseline characteristics, management, and outcomes of a cohort of 48 902 patients with 
COVID-19
Figure 1: Study flowchart
A complete admission was considered an outcome recorded at 28 days or 
earlier, and could either be a final outcome (eg, death or discharged alive) 
or documentation the patient remained in hospital. Relevant microbiological 
investigations were blood cultures, sputum, deep respiratory (endotracheal 
aspirates, bronchoalveolar lavage, and pleural fluid), urine, abdominopelvic, 
or pus samples from abscesses. *Some patients had both a COVID-19 related 
and unrelated infection.
55 452 patients in REDCap database on June 8, 2020
48 902 with complete admission recorded and confirmed (n=46 683) 
or high likelihood (n=2219) of SARS-CoV-2 infection
8649 with relevant microbiological investigations recorded
3191 with positive result(s)
1942 with microbiologically confirmed infections*
1107 COVID-19-related infections—blood, sputum, or deep 
respiratory
1002 Infections unrelated to COVID-19—urine, intra-abdominal, 
miscellaneous
6550 excluded
1792 with negative SARS-CoV-2 PCR
4758 with incomplete admission
40 253 with no microbiological investigations recorded in database
5458 with no positive microbiology result
1249 with contaminant or commensal or positive microscopy only
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infrequently cultured (five [4·2%] of 118 organisms). 
Among deep respiratory samples identifying co-infection, 
S aureus was the predominant organism (14 [31·1%] 
of 45 organisms). S aureus was also a common cause 
of secondary lower respiratory tract infections 
(sputum 81 [12·6%] of 642 organisms; deep respiratory 
29 [10·5%] of 277 organisms), but most organisms were 
Gram-negative, including Escherichia coli (sputum 
93 [14·5%] of 642 organisms; deep respiratory 40 [14·4%] 
of 277 organisms), P aeruginosa (sputum 80 [12·5%] 
of 642 organisms; deep respiratory 26 [9·4%] of 
277 organisms), Klebsiella pneumoniae (sputum 76 [11·8%] 
of 642 ogranisms; deep respiratory 32 [11·6%] of 
277 organisms), Klebsiella aerogenes (sputum 40 [6·2%] 
of 642 organisms; deep respiratory 25 [9·0%] of 
277 organisms), and Citrobacter koseri (sputum 26 [4·0%] 
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of 642 organisms; deep respiratory 20 [7·2%] of 
277 organisms).
When stratified by critical care admission status, 
174 (72·8%) of 239 organisms were identified from deep 
respiratory samples obtained more than 1 day after critical 
care admission (figure 2B). Deep respiratory samples 
included bronchoalveolar lavage, endotracheal aspirate, 
and other distal lung samples; the microbiological results 
from each of these sample types were similar 
(appendix pp 3, 5). In the critical care setting, E coli was 
the most common cause of lower respiratory tract 
infections (sputum 76 [14·8%] of 514 organisms; deep 
respiratory 33 [13·8%] of 239 organisms), followed by 
K pneumoniae (sputum 66 [12·8%] of 514 organisms; 
deep respiratory 28 [11·7%] of 239 organisms), S aureus 
(sputum 56 [10·9%] of 514 organisms; deep respiratory 
25 [10·5%] of 239 organisms), and P aeruginosa (sputum 
55 [10·7%] of 514 organisms; deep respiratory 25 [10·5%] 
of 239 organisms). Several opportunistic organisms—
such as C koseri, Stenotrophomonas maltophilia, and 
Morganella morganii—were cultured from respiratory 
samples obtained in critical care. Among non-critical care 
patients, S aureus was the most common organism in 
sputum (49 [18·6%] of 264 organisms) and deep 
respiratory samples (18 [20·2%] of 89 organisms), followed 
by P aeruginosa (sputum 38 [14·4%] of 264 organisms; 
deep respiratory none of 89 organisms), E coli (sputum 
27 [10·2%] of 264 organisms; deep respiratory ten [11·2%] 
of 89 organisms), and H influenzae (sputum 26 [9·8%] 
of 264 organisms; deep respiratory three [3·4%] of 
89 organisms).
Sputum microbiology differed between patients with 
and without chronic lung disease (figure 2C). Although 
S aureus (71 [13·5%] of 527 organisms), E coli (64 [12·1%] 
organisms), and K pneumoniae (56 [10·6%] organisms) 
were the predominant organisms detected in patients 
without chronic respiratory disease, P aeruginosa 
(41 [18·0%] of 228 organisms), E coli (34 [14·9%] 
organisms), and S aureus (34 [14·9%] organisms) were 
the most frequently isolated in those with chronic lung 
disease. Aspergillus fumigatus was also cultured from 
deep respiratory samples in four patients with chronic 
lung disease, three of whom were immunocompromised 
(clinician-defined or in receipt of immunomodulatory 
therapy before admission to hospital). We observed no 
other major differences in lower respiratory tract 
microbiology stratified by immune status (figure 2D).
With regard to blood cultures, 500 clinically significant 
results were recorded (appendix p 1). E coli (104 [20·8%] of 
500 organisms) was the most frequently identified 
pathogen, followed by S aureus (59 [11·8%]; figure 2) 
and K pneumoniae (33 [6·6%]; figure 2). Pneumococcal 
bacteraemia was uncommon (nine [1·8%] of 500 organisms). 
In bacteraemia occurring more than 1 day after admission 
to critical care, Enterococcus faecium (16 organisms) and 
K pneumoniae (15 organisms) were the most common 
pathogens. Candidaemia (12 organisms) was also more 
common. We observed no major differences when patients 
were stratified by immune status but viridans group strepto-
cocci and P aeruginosa were over-represented in patients 
with chronic lung disease. To determine the source of 
bacteraemia, we identified patients with the same organism 
Figure 2: Cause of microbiologically confirmed respiratory and bloodstream infections
The ten most identified pathogens from sputum, deep respiratory, and blood cultures, as a percentage of all positive samples of that type. The number at the end of each bar represents the total 
number of positive samples for the pathogen. Numbers annotated on the plots indicate the total number of organisms for each subgroup. Deep respiratory samples are endotracheal aspirates, 
bronchoalveolar lavage, and pleural fluid. Pathogen identification is stratified into sample obtained <2 days (co-infection) or >2 days (secondary infection) from admission to hospital (A); sample 
obtained <1 day or >1 day after admission to critical care (B); presence or absence of chronic pulmonary disease (C); and presence or absence of immunocompromise (D). S aureus=Staphylococcus 
aureus. H influenzae=Haemophilus influenzae. P aeruginosa=Pseudomonas aeruginosa. E coli=Escherichia coli. S marcescens=Serratia marcescens. S pneumoniae=Streptococcus pneumoniae. 
K pneumoniae=Klebsiella pneumoniae. M catarrhalis=Moraxella catarrhalis. K aerogenes=Klebsiella aerogenes. C koseri=Citrobacter koseri. E cloacae=Enterobacter cloacae. K oxytoca=Klebsiella oxytoca. 
M morganii=Morganella morganii. C freundii=Citrobacter freundii. P mirabilis=Proteus mirabilis. S maltophilia=Stenotrophomonas maltophilia. E faecalis=Enterococcus faecalis. E 
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isolated from another sample type. Generally, we found 
little overlap between blood and other cultures, with more 
overlap observed for sputum and deep respiratory samples 
compared with other samples (appendix p 4). S aureus was 
cultured from a sputum sample in nine (15·0%) of 
60 patients with S aureus bacteraemia. Despite the frequency 
of E coli bacteraemia, E coli bacteriuria in the same patients 
was infrequently identified (appendix p 4).
39 258 (85·2%) of 46 061 patients with inpatient 
antimicrobial data received one or more antimicrobials at 
some point during their admission. Antimicrobial use 
was highest in March and April, 2020, both among 
patients admitted and not admitted to critical care (figure 
3A). This proportion reduced over the course of May, 
2020. We found substantial regional differences in 
prescribing, in both the proportion of patients given 
antimicrobials (figure 4; appendix pp 6–7) and the type of 
antimicrobial prescribed (appendix pp 6–7). Across all 
regions, a higher proportion of patients admitted to 
critical care received antimicrobials compared with ward-
level patients. The proportion of patients receiving 
antimicrobials fell or remained static across most 
regions; the largest decline was observed in Scotland in 
critical care (150 [87·2%] of 172 patients in March, 2020, 
to 12 [66·7%] of 18 patients in May, 2020), and in the 
southwest of England in ward-level care (678 [82·7%] of 
820 patients in March, 2020, to 200 [63·9%] of 313 patients 
in May, 2020). Amoxicillin was more commonly 
prescribed in Scotland and Wales compared with 
England, whereas co-amoxiclav prescription was higher 
in England than Scotland and Wales, particularly among 
ward-level patients (appendix pp 6–7). Piperacillin-
tazobactam prescription among ward-level patients was 



































































































































































































































































































































Admitted to critical care
Admitted to critical careMaximum level of care
Figure 3: Frequency and nature of antimicrobial use
(A) The proportion of inpatients receiving antimicrobials between March and June, 2020, stratified by level of care. Data show rolling mean over a window of 14 days. 
Dotted lines represent 95% CIs. (B) Specific antimicrobials used, stratified by level of care or critical care. Co-use of specific antimicrobials in patients receiving 
ward-level care (C) and patients admitted to critical care (D), highlighting antimicrobials used for lower respiratory tract infection (blue box and shading), a signature 
of prescribing in response to penicillin allergy (green box and shading), carbapenem and glycopeptide usage in critical care (D only; blue box) and piperacillin–
tazobactam and carbapenem in critical care (D only; orange box). The greater the intensity of red shading, the greater the correlation of antimicrobial use 
measured by Jaccard distance. Dendrograms show the result of hierarchical clustering. Data available for 46 061 patients.
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the northwest, southwest, east, and northeast and 
Yorkshire, compared with other regions.
β-lactam–β-lactamase inhibitor combinations were 
among the top three most prescribed antimicrobials, 
accounting for 30·0% of total prescriptions (co-amoxiclav 
19·2%, piperacillin–tazobactam 10·8%; figure 3B). 
Narrower-spectrum antimicrobials used for the treatment 
of lower respiratory tract infections accounted for fewer 
prescriptions (amoxicillin 10·2% and doxycycline 8·9%). 
Consistent with lower respiratory tract infections being 
a major indication for antimicrobial use in this cohort, 
hierarchical clustering identified a cluster of clari-
thromycin, β-lactam–β-lactamase inhibitors, amoxicillin, 
and doxycycline in patients receiving ward-level care 
(figure 3C). The strongest correlation for co-receipt was 
between co-amoxiclav and clarithromycin (Jaccard 
simi larity coefficient 0·29). We observed a similar cluster 
in patients admitted to critical care, but this did not include 
amoxicillin or doxycycline (figure 3D). A cluster of the 
combination of a glycopeptide with ciprofloxacin was 
observed in patients receiving both ward-level (figure 3C) 
and critical care (figure 3D). Among patients admitted 
to critical care, a high proportion received piperacillin–
tazobactam, carbapenems, and glycopeptides, with 
evidence of co-prescription of carbapenem and glyco-
peptide (figure 3D), as well as piperacillin–tazobactam and 
carbapenem (figure 3D). Carbapenems accounted for 
3·8% of all prescriptions, whereas carbapenem-sparing 
Gram-negative active alternatives14 were less frequently 
prescribed (co-trimoxazole 1·5%, temocillin 0·3%, and 
aztreonam 0·2%). Almost half of prescriptions involved 
WHO AWaRe watch antimicrobials (appendix p 8).
Discussion
In this multicentre, prospective cohort of 48 902 patients 
admitted to hospital with COVID-19, microbiologically 
confirmed infections were infrequent (1107 patients). 
Co-infection at hospital admission was rare and when 
infections were identified, most were secondary. 
Gram-negative organisms and S aureus were the most 
frequently recovered pathogens from respiratory and 
blood cultures. These findings have implications 
for empirical therapy, indicating a need to treat 
Gram-negative bacteria and S aureus empirically until 
culture results are available. Most patients received 
antimicrobials, which were commonly broad spectrum. 
We found geographical heterogeneity in antimicrobial 
usage, reflecting variations in regional and local practices.
Our findings support and add granularity to those of a 
living systematic review and meta-analysis of 38 studies 
that examined bacterial infections in patients with 
COVID-19.8 Langford and colleagues reported a pooled 
prevalence of confirmed bacterial infections of 8·0% 
(95% CI 6·1–9·9), with a higher prevalence of secondary 
infections (16·0%, 12·4–19·6) than co-infections (4·9%, 
2·6–7·1).8 Although this meta-analysis included more than 
6000 patients, most of the included studies were 
retrospective and small (13 studies had <50 patients). 
Moreover, the timing of infection, microbiological details, 
and antimicrobial use were infrequently reported. By 
contrast, we included microbiological data derived from 
standardised laboratory investigations15 from a cohort of 
nearly 50 000 patients. We restricted analyses to clinically 
significant results, correlated with the timing of sample 
collection, and described antimicrobial use over time and 
by geographical region. The multicentre design of our 
study improves the generalisability of our findings.
The pattern of infection and associated pathogens in our 
cohort of patients with COVID-19 differs from that 
reported in influenza. S aureus and H influenzae were the 
most common (but infrequent) co-infecting respiratory 
pathogens, and bacteria identified in secondary infections 
and critical care were predominantly Gram-negative 
organisms, including Enterobacteriaceae and P aeruginosa, 
in addition to S aureus (ie, organisms typically identified 
in hospital-acquired or ventilator-acquired pneumonia). 
By contrast, bacterial co-infections are much more 





By region and critical care admission
Antibiotic use over time Proportion of patients that received inpatient
antimicrobial therapy in the region
0 25 50 75 100
Figure 4: Geographical variation in antimicrobial use over time
Maps are divided into Scotland, Wales, and regions of England (northeast and Yorkshire, northwest, midlands, 
east, southeast, southwest, and London). Purple shading of regions represents the percentage of patients who 
received antimicrobial therapy during their hospital admission, stratified by month of admission (March, April, and 
May) and by level of care (ward-level or critical care). Data available for 46 061 patients.
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predominantly caused by S pneumoniae or S aureus.1 Other 
studies of patients with COVID-19 have identified S aureus 
as a frequent cause of infection, including bacteraemia. 
We were unable to definitively determine the sources of 
bacteraemia in our study. However, in a case series of 
S aureus bacteraemia in 41 patients with COVID-19, most 
cases of bacteraemia were of unknown origin (69%), 
followed by pneumonia (19%), then vascular causes, 
including vascular access devices (7·1%).16 Exclusion of 
coagulase-negative staphylococci from our analysis might 
have led to the under-ascertainment of central line-
associated bloodstream infections.
Despite little evidence of bacterial infections in our 
cohort, a high proportion of patients received anti-
microbials. This finding is consistent with a meta-analysis 
that reported a pooled prevalence of antimicrobial usage 
of around 75% in patients with COVID-19.9 Elevated 
C-reactive protein and radiological pulmonary infiltrates 
are often used to differentiate bacterial from viral causes in 
community-acquired pneumonia. However, both of these 
findings are commonly present in patients with 
COVID-19.17,18 In a Scottish survey, C-reactive protein levels 
of at least 100 mg/L and chronic obstructive pulmonary 
disease or chronic lung disease were positively associated 
with antimicrobial prescribing.19 Combined with high 
morbidity and mortality, the absence of effective 
therapeutic options for COVID-19 during the study period, 
and clinical uncertainty during acute illness, high rates of 
antimicrobial prescription are unsurprising. Nevertheless, 
the infrequency of confirmed co-infection supports 
restrictive empirical antimicrobial usage. Anti microbials 
should be restricted to individuals with atypical features of 
COVID-19, such as purulent sputum or lobar pneumonia, 
or evidence of distinct non-respiratory co-infection. Blood 
and sputum cultures before empirical antimicrobial 
treatment and incorporating trends in inflammatory 
markers into decision making could also support judicious 
antimicrobial use. The absence of an elevated white cell 
count at baseline and antimicrobial-associated C-reactive 
protein reduction can exclude co-infection in around 
50% of patients with COVID-19.20 Procalcitonin might be 
an additional decision-making adjunct, using a threshold 
of 0·25 ng/mL or less to identify patients with a reduced 
likelihood of bacterial infection.21 Regular review of 
drug charts with discontinuation of antimicrobials if co-
infection is deemed unlikely, supported by negative 
microbiological investigations, are also key to minimise 
unnecessary antimicrobial exposure. When antimicrobials 
are required, the choice of antimicrobial should be tailored 
to likely pathogens and local resistance patterns, with 
treatment duration limited to 5 days if lower respiratory 
tract infection is suspected.6,7,22 Co-prescription of 
glycopeptides and ciprofloxacin was identified, which we 
postulate is a signature of prescribing in response to 
penicillin allergy labels. Many patients can be de-labelled 
without the need for penicillin challenges, associated with 
reduced broad-spectrum antimicrobial use, and this 
strategy should be encouraged in patients admitted to 
hospital with COVID-19 in advance of a potential need for 
antimicrobials.23 Further more, we identified frequent use 
of broad-spectrum empirical therapy (β-lactam–β-lactamase 
inhibitors) for lower respiratory tract infections, empirical 
escalation from piperacillin–tazobactam to carbapenems 
in critical care, and preferential use of carbapenems over 
carba penem-sparing alternatives. These findings all 
represent tractable targets for antimicrobial stewardship.
In contrast to other studies,24 co-infection and 
secondary infection were not associated with inpatient 
mortality among patients admitted to critical care in our 
study. Evaluation of the association between co-infection 
and outcome using observational data is complex. First, a 
greater proportion of deaths within the study occurred 
early during the hospital stay; therefore, these patients 
had less time to undergo microbiological investigations 
or to acquire a secondary infection. Conversely, any 
observed association could be driven by prolonged 
treatment in hospital because of more severe disease or 
slower recovery—co-infection or secondary infection 
might simply be a marker of this. Additionally, more 
thorough investigations might be done in patients 
who appear likely to have a favourable prognosis with 
adequate treatment, and such patients might be younger 
with fewer comorbidities.
Our study has several limitations. Retrospectively 
assigning clinical significance to culture results can be 
challenging and is further restricted in this study, as 
clinical findings that would contribute to diagnosis 
of bacterial infection were not collected at the time of 
microbiological sampling. The absence of clinical 
correlation limits interpretation of the microbiological 
findings—eg, isolation of E coli from sputum could 
represent true infection but alternative explanations 
include airway colonisation or altered (post-antimicrobial) 
flora, particularly in patients with chronic lung disease. 
We were unable to differentiate colonisation from new 
infection for patients with chronic lung disease, as 
previous microbiology results were not available.
Microbiological diagnosis of bacterial or fungal 
co-infection is itself challenging, especially in the context 
of COVID-19. Fewer diagnostic procedures might have 
been done during the pandemic because of clinical 
pressure and concerns regarding health-care worker 
safety (particularly from aerosol generating procedures, 
such as bronchoalveolar lavage), and inter-site variation 
in microbiological sampling is likely.25 Less than 20% of 
our cohort had microbiological investigations recorded, 
which is lower than reported for community-acquired 
pneumonia in a recent UK-wide audit (sputum and 
blood cultures were done in 23·6% of patients and 
58·6% of patients, respectively).26 Low rates of 
microbiological sampling in patients with COVID-19 
have been reported elsewhere.27 Under-ascertainment of 
true bacterial infection might also be due to antimicrobial 
receipt before sampling, as well as low sensitivity of 
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culture-based diagnostics. We excluded serological 
investigations for fungi or atypical bacteria, and urinary 
antigen tests for pneumococci and Legionella sp, 
as these were inconsistently recorded and the galacto-
mannan assay cross-reacts with β-lactams.28 We also 
lacked the data required to address the recently proposed 
case definition for COVID-19-associated pulmonary 
aspergillosis.29 Furthermore, we were unable to 
characterise respiratory viral or Mycoplasma pneumoniae 
co-infections, as most UK laboratories discontinued 
routine multiplex respiratory virus PCR testing during 
the study period. Therefore, we might have missed 
fungal or atypical bacterial co-infection identified by 
serum or urinary antigen tests alone, and other 
respiratory pathogen infections usually diagnosed 
by PCR.
We suspect the preferential recording of positive 
microbiology results based on the high culture-positivity 
rates; this limits our ability to determine an accurate 
denominator (ie, total number of microbiological investi-
gations done); thus we have refrained from prevalence 
estimates. This factor might partly explain the apparently 
low rates of microbiological investigations we observed. 
The timing of initiation and duration of antimicrobial 
therapy, and data on antibiograms of identified orga nisms, 
were not recorded. Hence, we were unable to link 
infections with prescribed antimicrobials or resistance 
patterns—eg, the proportion of S aureus that are meticillin 
resistant. Nonetheless, this proportion is likely to be low 
due to low meticillin-resistant S aureus infection rates in 
the UK.30
In conclusion, microbiologically confirmed bacterial or 
fungal infections were rare in patients admitted to hospital 
with COVID-19 during the first wave of the pandemic in 
the UK. When such infections occurred, they were mostly 
secondary and were caused by Gram-negative organisms 
and S aureus. The epidemiology of bacterial and fungal 
infections might change as immunomodulatory therapy 
for patients with COVID-19 progresses. Short-term 
systemic corticosteroid use in outpatients has been 
associated with a small increased risk of sepsis, and IL-6 
inhibition outside clinical trials is associated with 
increased risk of bacterial infection.31,32 Prospective studies 
with standardised and comprehensive microbiological 
sampling before antimicrobial treatment are needed to 
characterise co-infections and secondary infections in 
patients with COVID-19. Tractable targets for antimicrobial 
stewardship interventions exist and should be prioritised.
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